Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Diphenhydramine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase III
Sponsor : Baptist Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lidocaine Versus Diphenhydramine to Achieve Local Anesthesia for Laceration Repairs
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 04, 2025
Lead Product(s) : Diphenhydramine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase III
Sponsor : Baptist Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ocrelizumab,Diphenhydramine,Methylprednisolone
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Roche Updates Phase III OCREVUS High Dose Study in Relapsing MS Patients
Details : Ocrevus (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage.
Product Name : Ocrevus
Product Type : Antibody
Upfront Cash : Inapplicable
April 02, 2025
Lead Product(s) : Ocrelizumab,Diphenhydramine,Methylprednisolone
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Obinutuzumab,Paracetamol,Diphenhydramine
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Accepts Genentech’s Gazyva sBLA for Lupus Nephritis
Details : Gazyva® (obinutuzumab) is a CD20-directed cytolytic antibody, which is currently being evaluated for the treatment of lupus nephritis.
Product Name : Gazyva
Product Type : Antibody
Upfront Cash : Inapplicable
March 05, 2025
Lead Product(s) : Obinutuzumab,Paracetamol,Diphenhydramine
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diphenhydramine
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Prophylactic Treatment of Oral Prochlorperazine for Acute Mountain Sickness
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2024
Lead Product(s) : Diphenhydramine
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diphenhydramine
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SM-1 vs. an Active Comparator in A Model of Transient Insomnia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2020
Lead Product(s) : Diphenhydramine
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diphenhydramine
Therapeutic Area : Sleep
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2017
Lead Product(s) : Diphenhydramine
Therapeutic Area : Sleep
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diphenhydramine
Therapeutic Area : Sleep
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 06, 2017
Lead Product(s) : Diphenhydramine
Therapeutic Area : Sleep
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diphenhydramine
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : Clinilabs
Deal Size : Inapplicable
Deal Type : Inapplicable
Pilot Study of a Combination Drug Product for Treatment of Short-term Insomnia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 02, 2016
Lead Product(s) : Diphenhydramine
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : Clinilabs
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diphenhydramine
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 16, 2013
Lead Product(s) : Diphenhydramine
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diphenhydramine
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 13, 2010
Lead Product(s) : Diphenhydramine
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable